New Frontiers in the Treatment and Management of Extensive Stage Small Cell Lung Cancer (SCLC): A Closer Look at the Role of New and Emerging Immunotherapy

A continuing medical education activity provided by NAMCP and AAMCN

This activity is an archive from the live session from the 2020 Fall Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from November 1, 2020 to March 1, 2022

Instructions for CME/NCPD: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This activity is supported by educational grants from
AstraZeneca and Merck Sharp & Dohme Corp.

Small cell lung cancer (SCLC) is an aggressive form of the disease that comprises 15% of all new lung cancer cases diagnosed each year and this type of lung cancer tends to grow and spread faster than non-small cell lung cancer (NSCLC). About 70% of people with SCLC will have cancer that has already spread at the time they are diagnosed. Outcomes for patients with SCLC are poor with a median survival of less than 1 year. SCLC is a disease with limited treatment options, presenting a strong unmet need, especially for patients with metastatic disease that has progressed on or after platinum-based therapy. Fortunately for patients with metastatic SCLC, there are several therapy options, including immunotherapies, that have been approved recently that have shown great promise in their ability to improve clinical outcomes.

The treatment options for SCLC are based mainly on the stage of the cancer, but other factors, such as a person’s overall health and lung function are also important. Sometimes, combination options or multiple therapies are used. More recently immunotherapies have become available that give clinicians a new option with improved safety and efficacy profiles in the fight against SCLC. Immune checkpoint inhibitors have recently become available for patients with extensive stage SCLC in many different treatment lines. Additionally, new clinical trial data and novel options have become available that shows the promise of immunotherapy in the first line setting of extensive stage SCLC. The concept of tailoring therapies based on clinical and molecular markers has transformed the management of SCLC.

Upon completion of this activity, participants will be able to:

  • Examine the clinical and economic burden of small cell lung cancer (SCLC), including factors that contribute to poor prognosis and increased costs

  • Review efficacy and safety data from recent trials with immunotherapy in patients with extensive stage SCLC in multiple lines of therapy

  • Assess biomarkers and techniques in development to optimize selection of patients with extensive stage SCLC for immunotherapy

  • Discuss strategies to manage immune-related adverse events in patients with extensive stage SCLC on immunotherapy regimens

  • Examine the managed care considerations of new and emerging immunotherapies by exploring where these agents fit in the evolving extensive stage SCLC treatment paradigm


Faculty: Joshua Bauml, MD
Assistant Professor of Medicine
Division of Hematology/Oncology
Perelman School of Medicine
University of Pennsylvania


Dr. Bauml serves as a consultant for AstraZeneca, Ayala, BMS, Boehringer Ingleheim, Celgene, Clovis, Guardant Health, Genentech, Inivata, Janssen, Merck, Regeneron, and Takeda. He has received grants/research support from AstraZeneca, Bayer, Carevive Systems, Clovis, Janssen, Merck, Novartis, and Takeda. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no real or perceived financial relationships to disclose.
Jeremy Williams has no real or perceived financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no real or perceived financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the National Association of Managed Care Physicians (NAMCP) and American Association of Managed Care Nurses (AAMCN). The National Association of Managed Care Physicians is accredited by the ACCME to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category 1 credit(s)TM. Each
physician should claim credit commensurate with the extent of their participation in the activity.

The American Association of Managed Care Nurses is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

Nurses who complete this activity and achieve a passing score will receive 1 hour in nursing continuing professional development.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hours toward CMCN recertification requirements.

This activity is supported by educational grants from
AstraZeneca and Merck Sharp & Dohme Corp.

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue